151 related articles for article (PubMed ID: 9638104)
21. [Benign prostatic hyperplasia: medical therapy].
Schlenker B; Gratzke C; Weidlich P; Seitz M; Reich O; Stief CG
MMW Fortschr Med; 2007 Aug; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of finasteride in the treatment of hematuria associated with benign prostatic hypertrophy].
Palou Redorta J; Gausa Gascon L; Salvador Bayarre J; Millán Rodríguez F; Segarra Tomás J; Villavicencio Mavrich H
Arch Esp Urol; 2002 Oct; 55(8):895-9. PubMed ID: 12455279
[TBL] [Abstract][Full Text] [Related]
23. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.
Andersen JT; Nickel JC; Marshall VR; Schulman CC; Boyle P
Urology; 1997 Jun; 49(6):839-45. PubMed ID: 9187688
[TBL] [Abstract][Full Text] [Related]
24. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
25. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
[TBL] [Abstract][Full Text] [Related]
27. Managing benign prostatic hyperplasia.
Barkin J
CMAJ; 1997 Apr; 156(7):978-9. PubMed ID: 9099163
[No Abstract] [Full Text] [Related]
28. Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions.
Roehrborn CG
Urology; 2002 Jun; 59(6):811-5. PubMed ID: 12031358
[TBL] [Abstract][Full Text] [Related]
29. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
Trinkler FB
Praxis (Bern 1994); 1997 Aug; 86(34):1305-6. PubMed ID: 9381019
[No Abstract] [Full Text] [Related]
30. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
Ravish IR; Nerli RB; Amarkhed SS
Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
[TBL] [Abstract][Full Text] [Related]
31. Benign prostatic hyperplasia (BPH).
Harv Mens Health Watch; 2006 Aug; 11(1):3. PubMed ID: 17111474
[No Abstract] [Full Text] [Related]
32. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
33. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Rigatti P; Brausi M; Scarpa RM; Porru D; Schumacher H; Rizzi CA;
Prostate Cancer Prostatic Dis; 2003; 6(4):315-23. PubMed ID: 14663474
[TBL] [Abstract][Full Text] [Related]
34. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Agha AH; Roy JB; Culkin DJ; Lyon K
Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
[TBL] [Abstract][Full Text] [Related]
35. Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons.
Wise GJ; Md EO
Curr Urol Rep; 2001 Aug; 2(4):285-91. PubMed ID: 12084253
[TBL] [Abstract][Full Text] [Related]
36. Current management and future trends in benign prostatic hyperplasia (BPH).
Fitzpatrick JM
Ir Med J; 1997 Nov; 90(7):256, 258. PubMed ID: 10036815
[No Abstract] [Full Text] [Related]
37. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
38. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
39. [Drugs against symptomatic, benign prostatic hyperplasia].
Johansen TE
Tidsskr Nor Laegeforen; 2002 Oct; 122(26):2544-5. PubMed ID: 12522881
[No Abstract] [Full Text] [Related]
40. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
